Biotech Stocks: Drug stocks gain; Myriad climbs on drug-licensing deal
marketwatch.com     22-May-2008            

Drug stocks gain; Myriad climbs on Flurizan deal BOSTON (MarketWatch) -- Drug stocks gained Thursday as Myriad Genetics Inc. shares climbed on news that the company has signed a deal with Swedish drug conglomerate H. Lundbeck A/S for the European commercialization of its Alzheimer's drug... [read full story]                    


View all news articles about*:
A/S Genetics Lundbeck Myriad Pfizer
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Merck faces another round of criticism

pharmiweb.co.uk     yesterday   66 related          

By Miriam Hill INQUIRER STAFF WRITER For the third time in three years, a prominent medical journal has criticized Merck & Co. for misrepresenting research on its now-withdrawn painkiller Vioxx. Merck & Co. endangered patients...                    

comments

Executive Moves: Keata Pharma

pharmiweb.co.uk     yesterday          

Lou Panini has been named director, business development, Keata Pharma, Inc. Mr. Panini has many years of experience in the pharmaceutical industry, having spent most of his career with Pfizer in Canada and Belgium. Mr. Panini...                    

comments

Pfizer pays $137 million for Cytos technology

pharmiweb.co.uk     18-Aug-2008          

Cytos Biotechnology has touched gold after getting involved with Pfizer’s drive into biologics. The two companies have signed an agreement, which will see Cytos receiving $137 million (150 million Swiss francs) for Pfizer’s use...                    

comments

Myriad Genetics (MYGN) Considering Separation of Molecular Diagnostic and Pharmaceutical Business

pharmiweb.co.uk     21 hrs ago          

More News related to Corporate News With earnings this morning, Myriad Genetics, Inc. (NASDAQ: MYGN) said its management will do a comprehensive review and consider a variety of strategic alternatives, including but not limited...                    

comments